Betta Pharmaceuticals Co Ltd

Betta Pharmaceuticals has a total equity of CNY 6.595 billion and total liabilities of CNY 3.97 billion, resulting in a debt-to-equity ratio of 0.38, which is relatively low compared to the industry median. The company's liquidity position is assessed as medium, with a current ratio of 0.82, indicating that its current assets are slightly below its current liabilities. Free cash flow for the period was CNY 67.64 million, while operating cash flow was CNY 911.26 million.

Profitability metrics show a return on equity (ROE) of 4.63% and a return on assets (ROA) of 2.89%. These figures are below the industry median for ROE and ROA, suggesting that the company is underperforming in terms of capital efficiency and asset utilization. The net income of CNY 305.33 million and operating income of CNY 418.37 million indicate a stable but modest profit margin.

The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed. The financial data does not provide a breakdown of revenue by product segment, but the company's focus on generic and branded drugs suggests a reliance on a few key therapeutic areas. There is no indication of geographic diversification in the provided data.

Looking at the growth trajectory, Betta Pharmaceuticals reported revenue of CNY 3.609 billion for the period. While the outlook for the current fiscal year is stable, there is no specific numeric delta provided for the next fiscal year. The company's capital expenditure was negative CNY 616.68 million, indicating a reduction in capital spending, which may signal a strategic shift or a focus on cost optimization.

The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could pose a challenge in the short term. However, the low dilution risk suggests that the company is not expected to issue additional shares in the near future, preserving shareholder value.

Recent events and filings do not indicate any major corporate actions or significant changes in the company's strategic direction. The analyst estimates suggest a generally positive outlook, with a mean price target of CNY 63.03 and a median price target of CNY 63.03. The mean recommendation of 2.20 indicates a slight bias towards a "buy" rating, with two strong-buy recommendations and one buy recommendation.